Send to

Choose Destination
See comment in PubMed Commons below
Nat Clin Pract Nephrol. 2008 Oct;4(10):530-1. doi: 10.1038/ncpneph0913. Epub 2008 Aug 19.

Comparing the efficacy of intravenous iron and oral iron in nondialysis patients with chronic kidney disease.

Author information

  • 1Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.


This Practice Point commentary discusses the findings and limitations of a phase III trial by Spinowitz et al. that compared oral and intravenous iron therapies in nondialysis patients with chronic kidney disease. In total, 304 patients were randomly assigned in a 3:1 ratio to receive either two 510 mg doses of intravenous ferumoxytol within 5+/-3 days or 200mg of elemental oral iron daily for 21 days. At day 35, hemoglobin levels had increased significantly more in patients who had received intravenous ferumoxytol than in those who had received oral iron therapy. Ferumoxytol was well tolerated. The superiority of ferumoxytol over other intravenous iron preparations, however, needs to be investigated, and optimal serum ferritin levels for the nondialysis CKD population need to be defined.


Publication Types

Publication Types

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk